Manufacturing

Medicago is building a 646,000-sf vaccine manufacturing complex in Quebec City, Canada. Designed by NFOE, the facility will support the production of approximately 50 million doses of recombinant quadrivalent influenza vaccine per year. The project has a construction cost of CAD$143 million and is expected to be fully operational in 2023.

Medicago is currently developing a vaccine for SARS-CoV-2 which has successfully induced a positive antibody response in mouse models. Human clinical trials are expected to begin in summer of 2020. 

Thermo Fisher Scientific is planning to build a $180 million viral vector development and manufacturing facility in Plainville, Mass. Featuring flexible and scalable production suites, the 290,000-sf structure will leverage advanced digital technologies to enhance operational efficiencies.

Biogen completed construction in late spring of 2020 on a leading-edge biologics manufacturing center in Luterbach, Switzerland. Representing an investment of $1.5 billion, the modular and flexible facility leverages Biogen’s latest strategies for fed-batch cell culture technologies and protein purification processes. Offering two cell manufacturing lines, the 260,000-sf complex features two production buildings, each housing four 15,000-liter bioreactors. The campus also provides laboratories, offices, maintenance buildings, and a warehouse.

Global pharmaceutical firm XBiotech is planning to construct a 30,000-sf R&D laboratory in Austin, Texas. The facility will accelerate the creation of innovative treatments for infectious diseases. The project will be sited on the company's 48-acre headquarters campus, which includes a 33,000-sf research and manufacturing center that is also undergoing expansion to accommodate greater output, a larger workforce, increased inventory, and around-the-clock production operations.

The Vaccines Manufacturing Innovation Centre (VIMC) is being constructed on an accelerated schedule in Oxford in the United Kingdom. Ground was broken on the £66 million project in April of 2020 and occupancy is expected in 2021, a year earlier than previously planned.

New guidance has been released by the U.S. Department of the Treasury which makes Paycheck Protection Program loans available to companies with 500 or fewer employees, as well as to firms that fall below the size standards set by the Small Business Administration. Construction companies, whose status is generally determined by average annual income threshold and not by number of employees, will benefit from this amendment to the previous announcement, which required a business to meet both criteria to be eligible.

The International WELL Building Institute (IWBI) has assembled a task force to address the role of the built environment in reducing the impact of SARS-CoV-2 and other respiratory infections. Aiming to define the critical role that buildings, organizations, and communities play in infectious disease management, the work will take a broad approach in considering both new and recurring agents that can affect large populations.

Novo Nordisk completed a $5.1 million tenant renovation and expansion project in March of 2020 in Fremont, Calif. In just four months, MAI Construction remodeled the subleased 44,000-sf facility to provide Asterias Biotherapeutics with leading-edge research, production, and office spaces to support the creation of innovative stem cell therapies. The four-phase project included the construction of new cGMP Grade B manufacturing labs, as well as a materials lift and canopy for the area's shipping and receiving area.

Hyundai Motor Company will break ground in October of 2020 on the Hyundai Mobility Global Innovation Center in Singapore (HMGICs). The 300,000-sf facility will be located on over ten acres in the Jurong Innovation District, an advanced manufacturing campus developed by JTC Corporation. Supported by funding from the Singapore Economic Development Board, the open innovation hub will accelerate the discovery of new sustainable mobility solutions.

The International Society for Pharmaceutical Engineering has announced the 2020 Facility of the Year Awards category winners. The awards include:

Regeneron Pharmaceuticals is constructing an $800 million manufacturing campus in East Greenbush, N.Y. The complex is now in the third and final phase of development, which includes an $188 million, 346,000-sf production facility; a 240,000-sf lab and office building; and a six-story, 1,050-space parking garage. BBL Construction Services is managing the project with completion expected by 2022.

The United Kingdom Atomic Energy Authority (UKAEA) is building a £22 million nuclear fusion research facility in Rotherham. Supporting the creation of advanced joining materials and components, the 26,900-sf structure will feature specialized testing suites that simulate the conditions inside a fusion reactor. The center is being constructed in the Advanced Manufacturing Park (AMP) to promote collaboration with the adjacent Nuclear Advanced Manufacturing Research Centre and the University of Sheffield’s Advanced Manufacturing Research Centre.

Samsung Electronics broke ground in March of 2020 on a $220 million research and development center in Hanoi, Vietnam. The 860,000-sf facility will support the creation of innovative mobile devices and applications, as well as providing laboratories for the study of artificial intelligence, big data, the internet of things, and 5G technologies. Comprising 16 stories above ground and three floors below grade, the building will include a staff gym, a rooftop garden, and a clubhouse. Completion is expected in late 2022.

The Dubai Electricity and Water Authority opened the 47,360-sf Research and Development Centre in March of 2020. Located at the Mohammed bin Rashid Al Maktoum Solar Park in the United Arab Emirates, the four-story facility offers laboratories for the development of leading-edge technologies for solar power, smart grid integration, energy efficiency, and water management systems. Accelerating the Fourth Industrial Revolution, the center will enable the creation of innovative 3D printing and additive manufacturing modalities.

Fujifilm Diosynth Biotechnologies began construction in March of 2020 on a $14.5 million campus in Billingham in the United Kingdom. Designed by Ryder Architecture, the project will support the creation of innovative biologic, vaccine, and gene therapy products. Accommodating approximately 300 employees, the campus will feature a 42,000-sf office building with an inviting welcome center. Completion is expected in March of 2021. Additional R&D laboratories and manufacturing facilities will be delivered in a subsequent phase of development.